Novavax 過去の業績
過去 基準チェック /06
Novavaxは49.9%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで36.2%毎年増加している。売上は減少しており、年平均7.7%の割合である。
主要情報
49.89%
収益成長率
53.82%
EPS成長率
| Biotechs 業界の成長 | 17.04% |
| 収益成長率 | -7.72% |
| 株主資本利益率 | n/a |
| ネット・マージン | -14.73% |
| 前回の決算情報 | 31 Mar 2026 |
最近の業績更新
Recent updates
ナラティブの更新 • Jun 02
NVAX: Bearish View Will Hinge On Sustained COVID Vaccine Demand Beyond XFG Update
Analysts have lifted their Novavax price target to $9 from $8, citing updated assumptions around slower revenue declines, higher profit margins, and a lower future P/E multiple as key drivers of the change. Analyst Commentary Recent research points to a more cautious tone around Novavax, even as price targets are adjusted.Seeking Alpha • May 30
Novavax: The Pivot To A Royalty Model Is Working, But It's Still A Hold
Summary Novavax maintains a Hold rating as it transitions to a royalty-driven model, with shrinking direct product sales and a focus on partner revenue. NVAX's COVID-19/flu vaccine partnership with Sanofi is operationally ready, but the seasonal COVID-19 market remains niche and unlikely to drive significant upside. Q1 2026 revenue was $140 million, with guidance reaffirmed at $230–$270 million for the year, mostly from royalties; cash runway extends into 2028. Pipeline catalysts, including C. diff vaccine progress and milestone inflows, are largely priced in; meaningful upside requires clinical and financial differentiation. Read the full article on Seeking Alphaナラティブの更新 • Apr 26
NVAX: Bearish View Will Hinge On Sustained COVID Vaccination Demand
Analysts have raised their blended price targets for Novavax by about $1 per share to a range of around $7 to $8, citing updated assumptions for COVID demand, refreshed 2026 revenue and expense forecasts, and the contribution from recent partnership agreements. Analyst Commentary Recent Street research around Novavax reflects a mix of caution and tempered expectations, even as price targets move slightly higher into the mid single digit range.ナラティブの更新 • Apr 11
NVAX: Bearish View Will Hinge On Future COVID Demand Execution
Analysts have modestly lifted their average price targets on Novavax shares, with several moving from the $6 to $7 range toward $8 as they update COVID demand assumptions and incorporate new guidance on future revenue, operating expenses, and licensing income. Analyst Commentary Recent Street research on Novavax reflects a cautious tone, even as some targets edge higher.ナラティブの更新 • Mar 28
NVAX: Bearish Outlook Will Depend On Pfizer Royalty And COVID Demand Assumptions
Novavax's average analyst price target has edged higher by about $1, as analysts refine their COVID assumptions, update revenue and expense forecasts for future years, and factor recent partnership economics into their models. Analyst Commentary Recent Street research around Novavax points to a cautious tone, even as price targets move slightly higher.ナラティブの更新 • Mar 14
NVAX: Cautious Outlook Will Hinge On Future Pfizer Royalty Execution
Narrative Update on Novavax The analyst price target for Novavax has increased by about $1 to a new consensus of $7, as analysts adjust their models for updated COVID demand assumptions, refreshed 2026 revenue and expense forecasts, and the impact of recent partnership and licensing agreements. Analyst Commentary Recent Street research on Novavax points to a mixed but generally cautious stance.
ナラティブの更新 • Feb 27
NVAX: Licensing And Royalty Streams Will Drive Future Cash Generation
Analysts have lifted their average price target on Novavax to about $13.78 from roughly $13.11, citing updated COVID demand assumptions, refreshed revenue and expense forecasts, and revised P/E expectations that incorporate recent guidance and licensing agreements. Analyst Commentary Recent Street research reflects a mix of cautious optimism and ongoing concern, with several firms adjusting their price targets and underlying models around Novavax's COVID franchise, expense profile, and licensing income.分析記事 • Jan 14
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 32% in the last...ナラティブの更新 • Nov 08
NVAX: Shifting To Licensing Will Drive Royalties And Upfront Payments
Novavax's analyst price target has been modestly reduced from $13.21 to $13.11 per share. This change reflects analysts' cautious optimism about the company's new licensing model, expected royalties, and commercial partnership opportunities.ナラティブの更新 • Oct 24
Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead
The analyst price target for Novavax has been raised from $12.50 to $13.21. This reflects analyst confidence in the company’s transition to a licensing model as well as opportunities for revenue from new partnerships and technology platforms.ナラティブの更新 • Sep 04
Global Vaccine Market Will Unlock Upside Despite Execution Risks
Novavax’s consensus price target was modestly reduced, primarily due to a slight decline in its future P/E ratio, bringing fair value down from $12.86 to $12.50. What's in the News Reports indicate that the Trump administration and Robert F.分析記事 • May 20
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 29% But Investors Aren't Buying For Growth
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the last...Seeking Alpha • Apr 28
Novavax: Grandiose Ambitions, Smart Strategy, But FDA Decision Adds To Challenges
Summary Novavax's recent performance shows improvement, but significant challenges persist, impacting long-term growth and stability. The company's financials have strengthened due to strategic moves, yet uncertainties in its COVID-19 vaccine remain. NVAX stock's rating maintained at "Hold" despite ongoing hurdles based on improved cash position and potential future opportunities. Investors should remain cautious, balancing optimism with awareness of persistent risks and market volatility. Read the full article on Seeking Alpha
新しいナラティブ • Apr 22
Sanofi Partnership And Pipeline Programs Will Expand Future Markets
Strategic partnerships and new vaccine programs could significantly boost Novavax's future revenue and market expansion efforts.Seeking Alpha • Apr 11
Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer
Summary Novavax's $500M Sanofi partnership with a potential $700M in milestones provides stability as the company transitions to a partnership-focused strategy. Health Secretary Kennedy's claim that single-antigen vaccines don't work for respiratory diseases caused Novavax stock to plummet 20%. FDA approval delay for Nuvaxovid jeopardizes a crucial $175M milestone payment, though Novavax has the financial flexibility to survive this setback. Despite significant regulatory and competitive risks, NVAX stock maintains a "Hold" rating as a speculative component for barbell portfolios. Read the full article on Seeking Alpha分析記事 • Apr 02
The Market Doesn't Like What It Sees From Novavax, Inc.'s (NASDAQ:NVAX) Revenues Yet As Shares Tumble 28%
Novavax, Inc. ( NASDAQ:NVAX ) shareholders that were waiting for something to happen have been dealt a blow with a 28...分析記事 • Mar 12
Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for Novavax, Inc. ( NASDAQ:NVAX ) shareholders, with the analysts delivering a substantial...Seeking Alpha • Jan 16
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)
Summary I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of relative weakness. The partnership with Sanofi offers significant benefits but does not assure it of ongoing success. My analysis remains cautious, emphasizing the need for careful consideration of Novavax's long-term viability and strategic moves. Read the full article on Seeking Alpha分析記事 • Dec 17
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...分析記事 • Nov 15
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target
Novavax, Inc. ( NASDAQ:NVAX ) defied analyst predictions to release its third-quarter results, which were ahead of...Seeking Alpha • Nov 13
Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway
Summary Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial cost reduction program set to refocus the company on 4 key value drivers. A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines. Despite effective products, reduced guidance and restructuring uncertainty make NVAX stock a hold, with the Sanofi partnership and upcoming milestones as a potential bullish catalyst. Read the full article on Seeking Alpha分析記事 • Nov 01
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues
Novavax, Inc. ( NASDAQ:NVAX ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Oct 31
Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
Summary Novavax' Q3 earnings are due on 6th November. The vaccine developer was part of Operation Warp Speed, receiving $1.8bn of funding from the US government to develop a COVID vaccine. Novavax succeeded, but Nuvaxovid came to the market too late to build market share and the company ended up making heavy losses. Sanofi has acquired the rights to nuvaxovid, paying Novavax $500m upfront, and will look to develop a COVID / Influenza combo vaccine using Novavax' technology. Unfortunately, Sanofi milestones and revenues aside, that leaves Novavax with few opportunities to generate revenue, which likely means its valuation will fall over time. Read the full article on Seeking AlphaSeeking Alpha • Sep 01
Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones
Summary Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.1 variant, but newer Omicron variants have outpaced it, limiting competitive advantage. Financial stability hinges on achieving key milestones in the Sanofi partnership and successful commercialization of new vaccines. Despite the Sanofi deal, maintaining a "hold" position is prudent given the high-risk nature of Novavax's future prospects. Read the full article on Seeking Alpha分析記事 • Aug 14
Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business
Novavax, Inc.'s ( NASDAQ:NVAX ) price-to-sales (or "P/S") ratio of 2x might make it look like a strong buy right now...Seeking Alpha • Aug 13
Novavax: Staying Long Despite Coming Up Short In Q2
Summary Novavax reported Q2 earnings with a miss on EPS and revenue, causing a drop in share price, but recovered after the earnings call. Novavax is making progress with internal vaccine candidates, Sanofi partnership, and potential market opportunities, despite disappointing Q2 earnings. I provide my thoughts on the quarter, and will highlight a few downside risks that investors should consider. I discuss my updated NVAX strategy. Read the full article on Seeking Alpha収支内訳
収支内訳
Novavax の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 26 | 596 | -88 | 127 | 0 |
| 31 Dec 25 | 1,123 | 440 | 150 | 0 |
| 30 Sep 25 | 1,065 | 342 | 195 | 0 |
| 30 Jun 25 | 1,079 | 423 | 230 | 0 |
| 31 Mar 25 | 1,255 | 479 | 302 | 0 |
| 31 Dec 24 | 682 | -187 | 324 | 0 |
| 30 Sep 24 | 885 | -285 | 444 | 41 |
| 30 Jun 24 | 988 | -294 | 437 | 41 |
| 31 Mar 24 | 997 | -399 | 427 | 41 |
| 31 Dec 23 | 984 | -545 | 457 | 0 |
| 30 Sep 23 | 1,050 | -549 | 464 | 0 |
| 30 Jun 23 | 1,597 | -587 | 513 | 0 |
| 31 Mar 23 | 1,359 | -1,155 | 505 | 0 |
| 31 Dec 22 | 1,982 | -658 | 489 | 67 |
| 30 Sep 22 | 1,847 | -1,322 | 411 | 0 |
| 30 Jun 22 | 1,291 | -1,476 | 366 | 0 |
| 31 Mar 22 | 1,403 | -1,318 | 331 | 0 |
| 31 Dec 21 | 1,146 | -1,744 | 298 | 0 |
| 30 Sep 21 | 1,204 | -1,075 | 273 | 0 |
| 30 Jun 21 | 1,182 | -950 | 252 | 0 |
| 31 Mar 21 | 919 | -615 | 196 | 0 |
| 31 Dec 20 | 476 | -418 | 143 | 0 |
| 30 Sep 20 | 205 | -273 | 92 | 0 |
| 30 Jun 20 | 50 | -93 | 43 | 0 |
| 31 Mar 20 | 18 | -115 | 35 | 0 |
| 31 Dec 19 | 19 | -133 | 34 | 0 |
| 30 Sep 19 | 16 | -150 | 35 | 0 |
| 30 Jun 19 | 21 | -177 | 36 | 0 |
| 31 Mar 19 | 29 | -182 | 34 | 0 |
| 31 Dec 18 | 34 | -185 | 34 | 0 |
| 30 Sep 18 | 39 | -186 | 34 | 0 |
| 30 Jun 18 | 39 | -186 | 34 | 0 |
| 31 Mar 18 | 35 | -186 | 34 | 0 |
| 31 Dec 17 | 31 | -184 | 34 | 0 |
| 30 Sep 17 | 26 | -190 | 34 | 0 |
| 30 Jun 17 | 21 | -212 | 40 | 0 |
| 31 Mar 17 | 17 | -247 | 45 | 0 |
| 31 Dec 16 | 15 | -280 | 47 | 0 |
| 30 Sep 16 | 16 | -302 | 47 | 0 |
| 30 Jun 16 | 19 | -269 | 43 | 0 |
| 31 Mar 16 | 31 | -210 | 36 | 0 |
| 31 Dec 15 | 36 | -157 | 31 | 0 |
| 30 Sep 15 | 37 | -110 | 27 | 0 |
| 30 Jun 15 | 39 | -96 | 23 | 0 |
質の高い収益: NVAXは現在利益が出ていません。
利益率の向上: NVAXは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: NVAXは利益を出していないが、過去 5 年間で年間49.9%の割合で損失を削減してきた。
成長の加速: NVAXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: NVAXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 54.5% ) と比較することは困難です。
株主資本利益率
高いROE: NVAXの負債は資産を上回っているため、自己資本利益率を計算することは困難です。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/15 12:42 |
| 終値 | 2026/06/12 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Novavax, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23
| アナリスト | 機関 |
|---|---|
| Alec Stranahan | BofA Global Research |
| David Lebowitz | Brean Capital Historical (Janney Montgomery) |
| Mayank Mamtani | B. Riley Securities, Inc. |